PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Arcutis Biotherapeutics, Inc. (ARQT)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS03969K1088
CUSIP03969K108
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$1.10B
EPS-$3.78
Revenue (TTM)$59.61M
Gross Profit (TTM)$2.93M
EBITDA (TTM)-$239.58M
Year Range$1.76 - $15.40
Target Price$18.00
Short %20.45%
Short Ratio2.77

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ARQT

Arcutis Biotherapeutics, Inc.

Popular comparisons: ARQT vs. SPY

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Arcutis Biotherapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%OctoberNovemberDecember2024FebruaryMarch
-56.01%
62.72%
ARQT (Arcutis Biotherapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Arcutis Biotherapeutics, Inc. had a return of 196.90% year-to-date (YTD) and -6.35% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date196.90%10.04%
1 month-1.03%3.53%
6 months71.86%22.79%
1 year-6.35%32.16%
5 years (annualized)N/A13.15%
10 years (annualized)N/A10.96%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
202481.73%75.13%
2023-21.72%-37.82%-57.63%-18.22%75.54%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for Arcutis Biotherapeutics, Inc. (ARQT) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ARQT
Arcutis Biotherapeutics, Inc.
-0.07
^GSPC
S&P 500
2.76

Sharpe Ratio

The current Arcutis Biotherapeutics, Inc. Sharpe ratio is -0.07. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00OctoberNovemberDecember2024FebruaryMarch
-0.07
2.76
ARQT (Arcutis Biotherapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Arcutis Biotherapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-74.07%
0
ARQT (Arcutis Biotherapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Arcutis Biotherapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Arcutis Biotherapeutics, Inc. was 95.02%, occurring on Nov 30, 2023. The portfolio has not yet recovered.

The current Arcutis Biotherapeutics, Inc. drawdown is 74.07%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-95.02%Feb 9, 2021708Nov 30, 2023
-51.71%Mar 24, 2020155Oct 30, 202067Feb 8, 2021222
-39.4%Mar 11, 20206Mar 18, 20202Mar 20, 20208
-6.89%Feb 27, 20202Feb 28, 20207Mar 10, 20209
-4.64%Feb 25, 20201Feb 25, 20201Feb 26, 20202

Volatility

Volatility Chart

The current Arcutis Biotherapeutics, Inc. volatility is 27.35%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%OctoberNovemberDecember2024FebruaryMarch
27.35%
2.82%
ARQT (Arcutis Biotherapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Arcutis Biotherapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items